Benzinga | Oct 6, 2020 08:38AM EDT

OncoSec Announces Issuance Of New US Patent Expanding Coverage Of TAVO And Its Gene Delivery Platform

PENNINGTON, N.J. and SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intratumoral cancer immunotherapies, today announced the issuance of a new patent covering its interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO(tm). Specifically, on October 6, 2020, the United States Patent and Trademark Office issued U.S. Patent No. 10,792,375, entitled Method for the Treatment of Malignancies, which covers the Company's interleukin-12 (IL-12) based immunotherapy platform, including its lead product candidate TAVO(tm), and its proprietary EP gene delivery system. This patent covers the use of intratumoral electroporation of DNA encoding interleukins (such as IL-12) to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.

"This new patent further strengthens our core intellectual property estate, broadening the exclusivity of OncoSec's novel combination drug-device platform for the intratumoral delivery of immune-stimulatory interleukins," said Keir Loiacono, General Counsel and Vice President, Corporate Development at OncoSec. "The new IP serves to secure our competitive position in the intratumoral oncology space and builds on our patent portfolio of growing scope."